checkAd
    Startseite > Aktien > Acorda Therapeutics > Nachrichten
    Acorda Therapeutics Aktie
    ISIN: US00484M6012 · WKN: A2QLBW · USA

    Neueste Nachrichten

    Acorda Therapeutics Announces Delisting from Nasdaq
    15.04.24 · Business Wire (engl.) · Acorda Therapeutics
    Acorda Therapeutics Announces Nasdaq Delisting Notification
    03.04.24 · Business Wire (engl.) · Acorda Therapeutics
    Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement
    02.04.24 · Business Wire (engl.) · Acorda Therapeutics
    Acorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024
    01.04.24 · Business Wire (engl.) · Acorda Therapeutics
    Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024
    25.03.24 · Business Wire (engl.) · Acorda Therapeutics
    Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA by January 2025
    11.01.24 · Business Wire (engl.) · Acorda Therapeutics
    Acorda Therapeutics Reports Third Quarter 2023 Financial Results
    13.11.23 · Business Wire (engl.) · Acorda Therapeutics
    Acorda Third Quarter 2023 Update: Webcast/Conference Call Scheduled for November 13, 2023
    06.11.23 · Business Wire (engl.) · Acorda Therapeutics
    Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA
    06.11.23 · Business Wire (engl.) · Acorda Therapeutics
    Acorda Therapeutics Reports Second Quarter 2023 Financial Results
    08.08.23 · Business Wire (engl.) · Acorda Therapeutics
    Acorda Therapeutics Announces Launch of New INBRIJA Campaign: “For The Fighters”
    02.08.23 · Business Wire (engl.) · Acorda Therapeutics
    Acorda Second Quarter 2023 Update: Webcast/Conference Call Scheduled for August 8, 2023
    01.08.23 · Business Wire (engl.) · Acorda Therapeutics